Partnership / Collaboration · GCC · Announced 3 Nov 2025

IMGSA → Omani Investment

Algeria's IMGSA and an Omani pharma investment group agreed to build a US$20 million plant in Sohar Free Zone for antibiotics, oncology drugs and medical consumables, with trial production expected in 2027.

Parties: IMGSA (Algeria) → Omani Investment Group for Pharmaceutical Industry (Oman)

Value
$20m
Territory
Oman (Sohar Free Zone, 40,000 sq m site); phase one imports from Algeria
Therapeutic area
Multi-therapy
Assets
Antibiotics; Oncology treatments; Medical gloves; Sterile gauze and consumables
Announced
3 Nov 2025

Our analysis

Why this matters

On 3 November 2025, Algeria's IMGSA complex and the Omani Investment Group for Pharmaceutical Industry signed a strategic partnership for joint investment and transfer of technology and expertise to build an integrated plant in Sohar Free Zone, Oman. The investment is US$20 million on a 40,000 square-metre site. Planned output includes antibiotics, oncology treatments, medical gloves, sterile gauze and other medical consumables. Phase one involves importing raw materials and finished products from Algeria; trial production is expected in 2027. Algeria's ambassador to Oman and Sohar port and free-zone officials attended the signing.

For CEOs: this is an unusual flow, with a North African manufacturer exporting know-how into the Gulf rather than the reverse. Our reading is that Oman's free-zone incentives are attracting Arab mid-sized manufacturers, not only multinationals.

The full analysis is free to read with a work email on this page.

Source: Souq Al Dawaa Saudi

Latest deals

All GCC deals → · All partnership / collaboration deals → · Browse all emerging-market pharma deals →